When to Draw Phenytoin (Dilantin) Levels in Three-Times-Daily Dosing
For patients taking phenytoin three times daily, draw trough levels immediately before the morning dose (predose), as this provides the most reliable assessment of steady-state concentrations and helps avoid dose-related toxicity.
Timing Considerations
Trough Level (Primary Recommendation)
- Draw immediately before the next scheduled dose (predose/trough level)
- This represents the lowest concentration and is the standard for therapeutic drug monitoring 1
- Most reliable for assessing steady-state levels and preventing accumulation
Peak Level (When Indicated)
If peak levels are needed (typically for toxicity assessment):
- Draw 2-4 hours after an oral dose for immediate-release formulations 2, 3
- Studies show therapeutic levels are typically achieved within 2-3 hours after oral administration 3
- Peak concentrations occur at approximately 7-9 hours post-dose 2, 3
Timing Relative to Dose Initiation
After Loading Dose
- If oral loading was given: Check level 6-10 hours after completion of loading 4
- If IV loading was given: Check level immediately post-infusion and again at 12-24 hours 5
Steady-State Monitoring
- Wait 7-10 days before checking levels after starting therapy or changing doses 1
- This reflects phenytoin's pharmacokinetics requiring this duration to reach steady state
- Changes in dosage should not be made at intervals shorter than 7-10 days 1
Frequency of Monitoring
Initial phase:
- Check trough level after 7-10 days of stable dosing 1
Maintenance phase:
- Monitor periodically based on clinical response
- More frequent monitoring needed if:
- Seizure control is inadequate
- Signs of toxicity appear (ataxia, nystagmus, drowsiness)
- Interacting medications are added or removed
- Renal or hepatic function changes
Critical Pitfalls to Avoid
Low Albumin States
- Total phenytoin levels are misleading when albumin <3.5 g/dL 6
- Consider ordering free (unbound) phenytoin levels directly, or
- Calculate adjusted phenytoin using the Sheiner-Tozer equation 6
- Adjusted phenytoin provides superior classification, particularly at low albumin concentrations 6
Formulation Differences
- Dilantin extended-release capsules are NOT interchangeable with immediate-release formulations 1
- Extended-release formulations allow once-daily dosing but require careful monitoring when switching between products 1
- There is approximately an 8% difference in drug content between sodium salt and free acid forms 1
Therapeutic Range Context
- Target trough level: 10-20 mcg/mL (total phenytoin)
- Free phenytoin therapeutic range: 1-2 mcg/mL
- Levels >20 mcg/mL increase risk of dose-related toxicity (ataxia, nystagmus, cognitive effects)
Special Considerations
Three-times-daily dosing is the traditional divided dosing regimen 1. While once-daily dosing with extended-release formulations is possible for stable patients on 300 mg daily, this requires specific extended-release capsules and is not appropriate for all patients 1.
For patients on three-times-daily dosing who require level monitoring, the predose (trough) level before the morning dose remains the gold standard for therapeutic drug monitoring, as it minimizes variability and provides the most clinically useful information for dose adjustments.